

REMARKS/ARGUMENTS

The Restriction action dated 2 August 2006 required election between claim groups I-III. Applicants herein elect claim group I, including claims 4-7, 13-16 and 20, and generic claims 1-3 and 10-12. Claims 3-5, 7-9, 12-15 and 17-19 are cancelled without prejudice or disclaimer.

Claim 1 is amended to incorporate the subject matter of cancelled claims 3-5. Claim 6 is amended to incorporate the subject matter of cancelled claim 7. Claim 10 is amended to incorporate the subject matter of cancelled claims 12-15. Claim 16 is amended to correct dependency. Claim 20 is amended as an independent claim which includes the language of cancelled claim 5 and claim 7. No new matter is added by this amendment.

Conclusion

It is believed that this document is fully responsive to the Restriction requirement raised in the Restriction action dated 2 August 2006. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

Fees

It is believed that no fee is due with the submission of this response. In the event it is determined that a fee is due, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650 for the amount of that fee.

Respectfully submitted



Valeta Gregg, Ph.D., Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 593-1077 (direct)